Firm announcement “ No. 53 / 2024
Transactions in Zealand Pharma (NASDAQ:) shares and/or associated securities by individuals discharging managerial obligations and/or their carefully related individuals
Copenhagen, Denmark, December 25, 2024 “ Zealand Pharma A/S (Zealand) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology firm centered on the invention and improvement of revolutionary peptide-based medicines, has obtained info on transactions in Zealand Pharma’s shares or associated securities performed by individuals discharging managerial obligations and/or their carefully related individuals and hereby publishes the data on such transactions.
Please see the hooked up file(s).
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology firm centered on the invention and improvement of peptide-based medicines. Greater than 10 drug candidates invented by Zealand have superior into scientific improvement, of which two have reached the market and three candidates are in late-stage improvement. The corporate has improvement and partnership agreements with various pharma corporations in addition to industrial partnerships for its marketed merchandise.
Zealand was based in 1998 and is headquartered in Copenhagen, Denmark, with a presence within the U.S. For extra details about Zealand’s enterprise and actions, please go to www.zealandpharma.com.
Contact:
Neshat Ahmadi (Traders)
Investor Relations Supervisor
Electronic mail: neahmadi@zealandpharma.com
Adam Lange (Traders)
Investor Relations Officer
Electronic mail: alange@zealandpharma.com
Anna Krassowska, PhD (Media and Traders)
Vice President, Investor Relations & Company Communications
Electronic mail: akrassowska@zealandpharma.com
- 20241225 – Leonard Kruimer – Buy of shares
